IC 333 combines an effective treatment with enhanced drug delivery technology

Dry eye disease (DED) is a chronic inflammatory condition affecting 334 million people worldwide.

Cyclosporine is an immunosuppressant commonly used to treat DED by increasing tear production and improving tear film stability. Due to cyclosporine’s hydrophobic properties, current drug formulations rely on oil-in-water emulsions to deliver the drug to the tissues in the eye. This type of formulation is known to cause eye irritation, like a burning sensation, upon application.

IC 133 is a novel nano-enabled form of cyclosporine which is being developed for the treatment of dry eye. It uses nanoparticles of biocompatible polymers to wrap and solubilize cyclosporine in a protective cover, helping it across the barriers of the eye.

IC 133 has the potential to be more efficacious and better tolerated than current options on the market

10 times the delivery power

IC 133 has the potential to deliver more active drug than current treatment options on the market

More tolerable

IC 133 is free of oils, surfactants, and preservatives that can cause eye irritation

Targets the eye

IC 133’s formulation is targeted to allow cyclosporine to cross biological barriers, such as the cornea, to target ocular tissues without systemic exposure

Extended release

With IC 133’s advanced delivery system, simplified once a day dosing is possible

IACTA’s R&D in action

Because cyclosporine is hydrophobic, it is notoriously difficult to formulate and deliver to the target ocular tissues. Molecular Envelope Technology, MET, provides a superior delivery vehicle allowing for improved pharmacokinetics and performance versus the typical emulsion-based delivery technique.

Learn more about MET

View other products

IC 270

for allergic conjunctivitis

Learn more

IC 800

for acute pain relating to ocular post-surgical pain management

Learn more

IC 265

for the treatment of dry eye

Learn more